New preprint co-authored by CP3’s @jennylociganic.bsky.social: PGx can help match patients to safer opioids. An ensemble ML model (XGB+SVM-RBF) best predicted PGx uptake (AUC 79.6%). With further validation, it could support real-world clinical decision tools. www.medrxiv.org/content/10.1...

New study co-authored by CP3’s Dr. Ted Park finds over 1 in 5 opioid/benzo-naïve patients started 🆕Rx after surgery, while half with prior use continued. Many fills reflect preexisting use—highlighting need for tailored risk management. More @acsjacs.bsky.social: journals.lww.com/journalacs/a...

🆕study in 🫀co-authored by CP3’s @timandersonmd.bsky.social examines acute ⬆️ #bloodpressure in hospital settings. Clinicians often don’t treat it, citing uncertainty about dx thresholds & risks—highlighting need for clearer guidelines & decision support tools. More: heart.bmj.com/content/earl...

New study co-authored by CP3’s Dr. Coleman Drake finds that a 2008 federal #methadone supply restriction led patients to switch to safer formulations, preventing an estimated 1,600 #overdose deaths over two years. Read more: www.sciencedirect.com/science/arti...

We’re excited to share the launch of CP3’s new website, now hosted on the @openscholar.bsky.social platform! The site offers a fresh, unified look with other Pitt Centers and Institutes and is designed to spotlight CP3’s research projects. Take a look! cp3.pitt.edu

🆕preprint co-authored by CP3’s Dr. Julie Donohue finds ACA #Medicaid expansion in NJ & PA led to large immediate increases in Medicaid enrollment among people using homelessness assistance services, especially those with frequent service contact. www.researchsquare.com/article/rs-6...

🆕study w/ CP3 co-authors shows prescribers responded to the 2018-19 ARB (valsartan, losartan, irbesartan) recalls with large reductions in valsartan fills (↓ 57-59%), offset by increases in other ARBs. No major shift toward non-ARB antihypertensives. journals.lww.com/lww-medicalc...

🆕analysis led by CP3's Dr. Katie Suda & Tate Miner & team shows National Action Plan implementation wasn't associated with changes in antibiotic sales after 2 years. @mina-t.bsky.social @pittgim.bsky.social Read more @ichejournal.bsky.social: www.cambridge.org/core/journal...

New @journalgim.bsky.social study: VA clinicians cite evidence uncertainty, patient expectations, and system barriers as drivers of low-value care. Clearer guidance, education & aligned incentives may help reduce it. link.springer.com/article/10.1...

🆕paper, co-authored by CP3's @timandersonmd.bsky.social, describes findings that inpatient orthostatic hypotension was most often recognized after admission, but etiology and management differed across service lines. Read more: onlinelibrary.wiley.com/doi/10.1111/...

New analysis suggests restrictive state #opioid treatment program regulations limit geographic access to #methadone maintenance treatment & easing these restrictions could expand access. Read more in Health Affairs: www.healthaffairs.org/doi/10.1377/...

Though there were no differences in ED use or all-cause mortality, #Medicaid prescription cap policies were associated with increased hospitalization risk. Read more: www.sciencedirect.com/science/arti...

More than 1 in 10 opioid-naive #veterans having curative cancer surgery developed new persistent #opioid use, per a new study co-authored by CP3's Dr. Katie Suda. Optimizing pain management is key to reducing long-term opioid risks. More: acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Results suggest private equity acquisitions don't change #methadone access. Authors, incl CP3's Dr. Bryant Shuey, recommend policy makers be wary of those that "might benefit from the status quo on policies that seek to expand methadone access." More: www.healthaffairs.org/doi/10.1377/...

Not much is known about patterns of opioid prescribing & vaso-occlusive crises among individuals with sickle cell disease. CP3's Drs. Ted Park & Terri Newman & team sought to change that with this analysis. Learn what they found: www.thelancet.com/journals/lan...

CP3’s Dr. Tom Radomski received a new VA Merit grant to lead EVOLV-Rx VA, a study aimed at reducing low-value prescribing in VA Community Living Centers. The project will use an EVOLV-Rx dashboard to support pharmacists in making deprescribing recommendations. #Veterans #Deprescribing

🆕analysis from CP3's Dr. Ravy Vajravelu, @timandersonmd.bsky.social, Bridget Mayrer, & team examined the implications of recdent iron deficiency guidelines for the prevalence & management of iron deficiency anemia. Read more @jamainternalmed.com: jamanetwork.com/journals/jam...

Stimulant prescribing is ⬆️, leading to concerns about overprescribing/misuse. CP3's @timandersonmd.bsky.social & team examined post-Covid stimulant prescribing trends & noted ⬆️prescriptions by nurse practitioners & ⬆️marketing to clinicians. More @jamapediatrics.com: jamanetwork.com/journals/jam...

New paper co-authored by CP3’s #MachineLearning expert @jennylociganic.bsky.social presents a model that effectively predicts and stratifies risk of hepatitis C infection using ML algorithms—offering a powerful tool for targeted screening. Read more: academic.oup.com/ofid/article...

Congrats to @walidgellad.bsky.social & the mPROVEN study team on a new award to create a playbook for ethical use of #machinelearning based #opioid #riskprediction models, building on years of expertise developing & deploying these tools in a variety of care settings. www.cp3.pitt.edu/mproven

New study co-authored by CP3’s @timandersonmd.bsky.social finds orthostatic hypotension in hospitalized patients is often under-recognized, with only 1/3 resolving by discharge. Highlights need for better detection & treatment. Read more: onlinelibrary.wiley.com/doi/10.1111/...

Congrats to Dr. Kawtar Zouaidi (UT Health Houston) of Dr. Katie Suda's research team! Dr. Zouaidi's poster, “Adverse outcomes associated with high-risk medication administered to children during the dental visit, 2014-2020," received the Drug Utilization/HSR poster award at #ISPE!

CP3 Associate Director Dr. Katie Suda's team presented work from her NIH-funded Pediatric Adverse Event Risk Reduction R01 at the annual meeting of the International Society for Pharmacoepidemiology. #ISPE #pharmacoepi 1/2

🆕analysis found relationships between #antidepressant dose & fall risk, underscoring the importance of starting antidepressants at the lowest effective dose & monitoring fall risk. More: bmcmedicine.biomedcentral.com/articles/10.... Co-authored by CP3's Dr. Ted Park & @jennylociganic.bsky.social

CP3's @timandersonmd.bsky.social & other editors at @jamainternalmed.com describe challenges of using composite outcomes in clinical trials. jamanetwork.com/journals/jam...

In this analysis, led by CP3's @bryantshuey.bsky.social, a #Medicare 7-day limit on initial #opioid prescriptions was associated with immediate large reductions in initial opioid duration and dosage. CP3 associate director Dr. Katie Suda co-authored. Read more: journals.lww.com/annalsofsurg...

Though 27% of #Veterans surveyed reported being better able to afford 💊after co-pay restructuring, 29% reported worrying about paying for 💊, & 18% reported making tradeoffs to pay for prescriptions. Read more: journals.sagepub.com/doi/10.1177/... Co-authored by CP3's Dr. Katie Suda.

CP3's #MachineLearning expert @jennylociganic.bsky.social was part of a team that developed an #algorithm to effectively identify individuals at high risk of depression onset within the next 6 months & provides opportunity for early intervention. Read more: ebooks.iospress.nl/doi/10.3233/...

CP3's @jennylociganic.bsky.social & @walidgellad.bsky.social are part of a team awarded a grant to develop a ML algorithm to predict relapse in OUD tx and to build clinical decision support tool. The team includes colleagues from the University of FL & Dr. Praveen Kumar from Pitt Public Health. 1/2

Pittwire re-ran a 2024 story featuring CP3’s Dr. Lucas Berenbrok on the critical role of community pharmacies. His work shows nearly all Americans live near one—highlighting their value in closing care gaps. Read the piece: www.pittwire.pitt.edu/pittwire/pit...

PA lawmakers want to regulate #AI use in healthcare. At CP3, we've been thinking about this issue for years and wrote a paper published in #HealthAffairs in 2022. www.healthaffairs.org/content/fore... More on PA lawmakers via @wesa.fm: www.wesa.fm/politics-gov...

🆕JAMA Health Forum study: Medicare Advantage beneficiaries had 3.1% lower 30-day surgical costs vs Traditional Medicare, w/more outpatient care, shorter stays, fewer readmissions. Findings suggest MA care coordination drives savings. jamanetwork.com/journals/jam... @timandersonmd.bsky.social

CP3's Dr. Luke Berenbrok co-developed an interprofessional advanced training program on OTC hearing aids to educate how to recognize, intervene, & refer patients with hearing loss to hearing healthcare. Offered by the #AmericanPharmacistsAssociation. www.pharmacist.com/Education/Ad...

#Pittsburgh is making headlines for being an emerging leader in #AI. CP3 is proud to be at the forefront of using our expertise in AI & #machinelearning to improve patient care & safety. Get to know our innovative projects: www.cp3.pitt.edu/research/ris...

Today is National Women Touched by Addiction Day. At CP3, we’re committed to safer opioid prescribing and better access to medications for opioid use disorder. Explore our research on these efforts: www.cp3.pitt.edu/publications...

A new analysis adds to the evidence that housing is health. Benjamin Zhu & CP3's Tom Radomski found that patients experiencing unstable housing were more likely to report worse asthma control. Read more in the Journal of General Internal Medicine: link.springer.com/article/10.1...

Driving isn't the whole story! A 🆕study found that measuring pharmacy access only by driving time overlooks major inequities—over 2.4 million people in the 10 largest U.S. metro areas are affected when walking or public transit are factored in. Read more: pubmed.ncbi.nlm.nih.gov/40684915/

Congrats to CP3 Associate Director Dr. Katie Suda on being selected as the next Director of the VA Pittsburgh site of the Center for Healthcare Evaluation, Research, & Promotion (CHERP)! She's a phenomenal clinician-scientist, & we can't wait to see how CHERP will grow under her leadership!

Checklists are an effective way to improve patient safety in medication prescribing but depend on usability and workflow integration. Read more: www.japha.org/article/S154... With CP3's Yilei Liu, Tate Miner, & Dr. Katie Suda

Safety checklists are used in a variety of pediatric care settings--most associated w/⬇️ adverse events. This review emphasizes the continued need for checklists to improve safety & care quality. Read more: www.academicpedsjnl.net/article/S187... Co-authored by CP3's Tate Miner & Dr. Kate Suda

🆕VA community care eligibility was associated w/⬆️ in 💊overlap involving opioids & other CNS-active 💊- indicating need to monitor co-prescribing in community care. More: onlinelibrary.wiley.com/doi/10.1111/... w/CP3's @timandersonmd.bsky.social, Katie Suda, Tom Radomski, & @walidgellad.bsky.social

Higher-income countries have higher utilization of direct-acting antivirals than lower-income countries - study authors (including CP3's Dr. Katie Suda) suggest strategies for balancing access. Read more: pmc.ncbi.nlm.nih.gov/articles/PMC...

Study results show Veterans ⬆️received non-VA Rx thru community urgent care centers, including drug classes w/ potential risks of inappropriate prescribing or drug interactions. Read more: www.sciencedirect.com/science/arti... Co-authored by CP3's @walidgellad.bsky.social & Drs. Suda & Good

New work led by CP3 alum Dr. Patience Dow shows #Medicaid cap policies associated with ⬆️likelihood of early discontinuation & other trajectories of inconsistent #buprenorphine use. Co-authored by CP3's Dr. Julie Donohue. Read more: www.jsatjournal.com/article/S294...

Congrats to CP3's Dr. Luke Berenbrok for being one of 36 people selected to ‪@aacpharmacy.bsky.social‬ Academic Leadership Fellows Program! new.express.adobe.com/webpage/MW7H... #LeadershipDevelopment | #AACPALFP | #Pharmacy

At @academyhealth.bsky.social #ARM25, Dr. Joshua Devine of Des Moines U. presented research he led from CP3 Associate Director Dr. Katie Suda's AHRQ R01, Impact of COVID-19 on Drug Shortages. His poster was co-authored by Dr. Suda, @mina-t.bsky.social , & CP3 alum Dr. Inma Hernandez.

Join us in congratulating the brilliant @jennylociganic.bsky.social for her promotion to Full Professor w/ tenure @pittdeptofmed.bsky.social! Jenny was CP3's 1st postdoc, & we were thrilled when she re-joined the team. She makes our #machinelearning projects run & makes us have 10x more fun!

A study led by CP3 alum @uressien.bsky.social & co-authored by CP3's @walidgellad.bsky.social featured in @medscape.com. The team found that Black pts w/AFib had a much higher stroke risk than white pts. Read more: www.medscape.com/viewarticle/...

“There’s potential that there is a tradeoff here: Less alcohol and more loneliness, and we need to think about addressing both," CP3's @bryantshuey.bsky.social told @yahoonews.com about his study showing young men are binge drinking less than young women. Read more: www.yahoo.com/lifestyle/yo...

CP3's Drs. Aimee Pickering & Tom Radomski & team describe key barriers & facilitators to #deprescribing #diabetes meds, including patients' understanding of prescriber rationale & fear of negative consequences. Read more @agsjournal.bsky.social: agsjournals.onlinelibrary.wiley.com/doi/10.1111/...